STOCK TITAN

Director at Pacific Biosciences (PACB) receives 223,492 stock options grant

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Hannah Valantine received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share and expire on June 3, 2036.

The options will vest monthly over one year, or earlier on the date of the next annual meeting of the company’s stockholders after the grant date, as long as she continues serving as a director. Following this grant, she holds 223,492 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider Valantine Hannah
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 223,492 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy) — 223,492 shares (Direct)
Footnotes (1)
  1. F1. The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Options granted 223,492 options Stock Option grant to director on June 3, 2026
Exercise price $1.58 per share Conversion or exercise price of stock options
Underlying shares 223,492 common shares Underlying security shares for the option grant
Post-transaction derivative holdings 223,492 derivative securities Total derivative securities following the grant
Option expiration June 3, 2036 Expiration date of the stock options
Vesting schedule Monthly over 1 year Vests monthly or earlier at next annual stockholders’ meeting
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
conversion or exercise price financial
"conversion_or_exercise_price: 1.5800"
vest monthly financial
"The shares subject to the option will vest monthly over one (1) year"
annual meeting of the Company's stockholders financial
"on the date of the next annual meeting of the Company's stockholders"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did PACB director Hannah Valantine receive in this Form 4 filing?

Hannah Valantine received a grant of stock options for 223,492 shares. These options give her the right to buy PACB common stock at a fixed exercise price if they vest and she chooses to exercise.

What is the exercise price of the options granted to PACB director Hannah Valantine?

The options have an exercise price of $1.58 per share. This means she can purchase PACB common stock at $1.58 per share once the options vest and before they expire, regardless of the market price at that time.

How do the PACB stock options granted to Hannah Valantine vest?

The options vest monthly over one year, provided she remains a director. Vesting may end earlier on the date of the next annual meeting of the company’s stockholders after the grant date, if that occurs before the full year.

When do the PACB stock options granted to Hannah Valantine expire?

The options expire on June 3, 2036. She must exercise any vested portion before that expiration date; otherwise, unexercised options will lapse and no longer allow her to purchase PACB shares.

Did Hannah Valantine buy or sell PACB shares in the market in this Form 4?

No market purchases or sales are reported. The Form 4 shows a compensation-related grant of stock options, not open-market trading. It reflects an acquisition of derivative securities rather than buying or selling existing PACB shares.

How many PACB derivative securities does Hannah Valantine hold after this transaction?

After this grant, she holds 223,492 derivative securities directly. These represent stock options tied to PACB common shares, which she may choose to exercise in the future if they are vested and in force.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Valantine Hannah

(Last)(First)(Middle)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
1305 O'BRIEN DRIVE

(Street)
MENLO PARK CALIFORNIA 94025

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [ PACB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.5806/03/2026A223,49207/03/2026(1)06/03/2036Common Stock223,492$0223,492D
Explanation of Responses:
1. The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Remarks:
/s/ Brett Atkins, Attorney-in-fact06/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)